.png){kind=icon}
-
Overcoming Bottlenecks in Quantifying Oligonucleotide Therapeutics
White PapersApr. 01, 2020
Overcoming Bottlenecks in Quantifying Oligonucleotide Therapeutics: Using LC-MS/MS Technology and Expertise to Reduce Risk and Increase Your Speed to Market Developing bioanalytical solutions to support oligonucleotide drug programs can be challenging due to the unique physicochemical properties of these molecules. This whitepaper outlines both the established and the unique liquid chromatography and extraction technologies Covance has developed to ensure you remain at the forefront of oligonucleotide innovation. Learn how you can benefit from the workflows to: eliminate bottlenecks and accelerate timelines with state-of-the-art liquid chromatography, focused detection and extraction technologies that generate accurate and robust data, rapidly receive the results you need through world-class scientific expertise based on decades of experience in solving complex bioanalytical challenges and capitalize on the rapidly expanding oligonucleotide marketing with the support of technologies and expertise.
Overcoming Bottlenecks in Quantifying Oligonucleotide Therapeutics: Using LC-MS/MS Technology and Expertise to Reduce Risk and Increase Your Speed to Market Developing bioanalytical solutions to support oligonucleotide drug programs can be challenging due to the unique physicochemical properties of these molecules. This whitepaper outlines both the established and the unique liquid chromatography and extraction technologies Covance has developed to ensure you remain at the forefront of oligonucleotide innovation. Learn how you can benefit from the workflows to: eliminate bottlenecks and accelerate timelines with state-of-the-art liquid chromatography, focused detection and extraction technologies that generate accurate and robust data, rapidly receive the results you need through world-class scientific expertise based on decades of experience in solving complex bioanalytical challenges and capitalize on the rapidly expanding oligonucleotide marketing with the support of technologies and expertise.
